Cheaper MS drug could match pricey standard in major trial
NCT ID NCT04688788
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effectively as ocrelizumab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rituximab and ocrelizumab (drugs that target immune cells to reduce MS activity)
What this could lead to
If rituximab works as well as ocrelizumab, it could offer a more affordable treatment option for multiple sclerosis.
What could go wrong
This is a non-inferiority trial, so rituximab may turn out to be less effective or have different side effects. Results may not apply to all MS types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Danish Multiple Sclerosis Center, Rigshospitalet
Glostrup Municipality, Copenhagen, 2600, Denmark
-
Department of Neurology, Aalborg University Hospital
Aalborg, 9000, Denmark
-
Department of Neurology, Aarhus University Hospital
Aarhus, 8200, Denmark
-
Department of Neurology, Herlev Hospital
Herlev, 2730, Denmark
-
Department of Neurology, Hospital of South West Jutland, Esbjerg
Esbjerg, 6700, Denmark
-
Department of Neurology, Hospital of Southern Jutland, Sønderborg
Sønderborg, 6400, Denmark
-
Department of Neurology, Kolding Hospital
Kolding, 6000, Denmark
-
Department of Neurology, Nordsjællands Hospital i Hillerød
Hillerød, 3400, Denmark
-
Department of Neurology, Odense University Hospital
Odense, 5000, Denmark
-
Department of Neurology, Regionshospitalet Holstebro
Holstebro, 7500, Denmark
-
Department of neurology, Regionshospitalet Viborg
Viborg, 8800, Denmark